Cite
HARVARD Citation
Earl, H. et al. (2019). 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 393 (10191), pp. 2599-2612. [Online].